Gastroesophageal junction tumors

Gastroesophageal junction tumors constitute a heterogeneous group of malignant neoplasms arising in the anatomical and functional transition region between the distal esophagus and the proximal stomach. This area represents a complex biological crossroads, characterized by histological, physiological, and biomechanical features that make it particularly vulnerable to carcinogenic processes. Histopathologically, most of these neoplasms are adenocarcinomas, although overlapping features with esophageal and gastric tumors proper may coexist. Their intermediate anatomical location has major implications for classification, staging, and therapeutic strategy.

The natural history of gastroesophageal junction tumors results from the interaction between chronic exposure to mucosal injury, persistent inflammatory changes, and the progressive accumulation of genetic and epigenetic alterations. In many cases, carcinogenesis develops through a sequence that includes chronic inflammation, intestinal metaplasia, and dysplasia, similarly to what is observed in adenocarcinoma of the distal esophagus. However, proximity to the gastric mucosa introduces additional pathogenetic variables related to acid secretion, reflux composition, and the adaptive response of the transitional epithelium. In the early stages, the disease may remain clinically silent or present with subtle symptoms, whereas progression leads to obstruction, chronic bleeding, and deterioration of nutritional status.

The diagnosis and staging of gastroesophageal junction tumors require an integrated approach combining upper gastrointestinal endoscopy with targeted biopsies, endoscopic ultrasound to assess the depth of invasion and regional lymph-node involvement, and cross-sectional imaging to define locoregional and distant disease extent. In selected cases, metabolic assessment with PET helps identify occult disease sites and guide the therapeutic strategy. Treatment is generally multimodal and is planned by a multidisciplinary team, taking into account the precise location of the lesion, disease stage, and the patient’s general condition. Despite advances in integrated management, prognosis remains affected by the frequent diagnosis at an advanced stage and by the anatomical complexity of the site of origin.

The epidemiology of gastroesophageal junction tumors largely reflects the changes observed in the incidence of esophageal adenocarcinoma and proximal gastric cancer over recent decades. A significant increase in these neoplasms has been recorded in Western countries, in parallel with rising rates of obesity, gastroesophageal reflux, and conditions associated with modern lifestyles. In many regions of Europe and North America, junctional tumors now account for a substantial proportion of upper gastrointestinal malignancies, whereas their incidence remains lower in other areas of the world.

Geographical distribution shows marked differences, with a high incidence in high-income countries and lower rates in East Asia and Africa, where epidemiological patterns continue to be dominated by distal gastric cancers and esophageal squamous cell carcinoma. Variations related to socioeconomic factors, dietary habits, and access to healthcare are also evident within individual countries. This heterogeneity underscores the central role of environmental and behavioral determinants in disease development.

From a demographic standpoint, gastroesophageal junction tumors predominantly affect men, with male-to-female ratios comparable to those observed for esophageal adenocarcinoma. Diagnosis most often occurs in the sixth and seventh decades of life, although onset may occur earlier in the presence of multiple risk factors. Significant ethnic differences have been described, with a higher risk among individuals of Caucasian origin than among other groups, regardless of geographical location.

Chronic gastroesophageal reflux is one of the main risk factors because it exposes the junctional mucosa to prolonged contact with acid and bile, promoting persistent inflammation and epithelial remodeling. The presence of intestinal metaplasia in the cardia or distal esophageal region further increases the risk of neoplastic progression. The intensity and duration of reflux exposure, as well as the composition of the refluxate, influence individual risk.

Obesity, particularly visceral obesity, is a major independent determinant. In addition to promoting reflux through increased intra-abdominal pressure, adipose tissue contributes to a chronic systemic inflammatory state that may facilitate carcinogenesis. The risk associated with obesity has also been documented in individuals with mild or absent reflux symptoms, suggesting complex and multifactorial pathogenetic mechanisms.

Cigarette smoking is another risk factor, with a dose-dependent effect, whereas the association with alcohol consumption is less pronounced than for esophageal squamous cell tumors. Dietary factors, such as diets high in fat and low in fiber, fruit, and vegetables, may contribute to risk through metabolic and inflammatory mechanisms. Hiatal hernia is frequently found in patients with junctional tumors and acts as a factor facilitating chronic reflux.

The role of Helicobacter pylori in gastroesophageal junction tumors is complex and variable. In some populations, infection appears to have a protective effect, probably mediated by reduced gastric acid secretion, whereas in other settings it may coexist with predisposing mucosal alterations. This relationship remains under investigation and contributes to the geographical variability in incidence.

Overall, gastroesophageal junction tumors arise from the interaction of chronic reflux, obesity, individual susceptibility, and environmental factors. Understanding these determinants is essential for developing effective primary prevention strategies and identifying individuals who may benefit from targeted surveillance pathways.

For gastroesophageal junction tumors, population-based screening programs are not recommended, similarly to esophageal adenocarcinoma. Their relatively low incidence in the general population and the absence of reliable noninvasive tests make widespread endoscopy-based screening impractical. Early-detection strategies therefore focus on subgroups of patients with a substantially increased risk.

A central area for surveillance concerns individuals with Barrett esophagus or intestinal metaplasia of the cardia. In these patients, periodic endoscopic monitoring makes it possible to detect the onset of dysplasia or superficial carcinoma in the gastroesophageal transition zone at an early stage. Systematic biopsies performed according to standardized protocols are the main tool for assessing the histological evolution of the mucosa.

The interval between surveillance endoscopies is tailored to the individual risk profile and the degree of histological abnormality. In the absence of dysplasia, examinations may be spaced farther apart, whereas the presence of dysplasia requires closer monitoring and the integration of targeted endoscopic treatment. This approach allows early lesions to be treated while reducing the need for extensive surgical procedures.

In patients with chronic gastroesophageal reflux associated with multiple risk factors, such as male sex, older age, and obesity, diagnostic endoscopy may be considered to identify junctional abnormalities at an early stage. This strategy does not constitute universal screening, but rather a risk-stratification pathway designed to select candidates for surveillance.

Advanced endoscopic techniques, including chromoendoscopy and optical imaging methods, improve the ability to identify areas of dysplasia or superficial neoplasia at the junction, where lesions may be irregular or multifocal. The use of these technologies requires dedicated expertise and is generally concentrated in referral centers.

Innovative approaches based on minimally invasive cell-sampling devices and molecular biomarker analysis are being evaluated. Although promising, these strategies have not yet gained an established role in clinical practice and remain largely confined to research settings.

In summary, screening for gastroesophageal junction tumors is not indicated in the general population, whereas selective surveillance of high-risk individuals is a rational strategy. Incorporating endoscopic surveillance into structured clinical pathways can bring diagnosis forward and improve outcomes while avoiding unnecessary procedures in low-risk individuals.

Gastroesophageal junction tumors are a biologically heterogeneous group of neoplasms arising in the transition region between the distal esophagus and the proximal stomach, an area characterized by distinctive anatomical, functional, and microenvironmental conditions. The junction is a site of considerable epithelial plasticity, continuously exposed to mechanical and chemical stress, particularly chronic exposure to acidic and biliary contents. This setting promotes adaptive and inflammatory processes that may progress to neoplastic transformation through mechanisms shared with both esophageal adenocarcinoma and proximal gastric adenocarcinoma.

From a pathogenetic perspective, a substantial proportion of these tumors arise in the setting of chronic gastroesophageal reflux, with the development of intestinal metaplasia followed by progression through dysplasia to carcinoma, similarly to what occurs in Barrett esophagus. In other cases, especially lesions located more proximally toward the gastric cardia, carcinogenesis is associated with chronic gastric inflammatory processes, including mucosal atrophy and alteration of the glandular microenvironment. The result is a biological continuum in which the boundaries between distal esophageal and proximal gastric adenocarcinoma are blurred, with histological and molecular overlap.

A key event in progression is the disruption of glandular architecture and loss of control over cell polarity. Neoplastic cells acquire the ability to grow invasively through the basement membrane, extending into the submucosa and deeper layers. The rich lymphatic network of the junction facilitates early lymph-node dissemination, explaining the high frequency of involvement of perigastric, lower mediastinal, and celiac lymph nodes even in relatively small tumors. Depth of invasion and lymphovascular invasion are direct expressions of biological aggressiveness.

At the genetic level, gastroesophageal junction tumors show marked chromosomal instability. TP53 mutations are extremely common and represent an early event associated with loss of genomic surveillance. Amplifications of receptor and proliferative signaling genes, including ERBB2 (HER2), EGFR, MET, FGFR2, and CCND1, sustain persistent mitogenic signaling. Alterations in CDKN2A and dysregulation of cell-cycle checkpoints promote uncontrolled proliferation. In a subset of cases, defects in DNA-repair mechanisms lead to the accumulation of secondary mutations.

Major signaling pathways are altered, including PI3K/AKT/mTOR, MAPK, WNT/β-catenin, TGFβ, and pathways involved in the cellular stress response. Large-scale genomic studies have demonstrated substantial molecular heterogeneity, with patterns reflecting the anatomical origin and type of inflammatory exposure. This biological diversity translates into different clinical behaviors and variable sensitivity to systemic treatments.

Epigenetic alterations make a major contribution to pathogenesis. Hypermethylation of tumor-suppressor gene promoters, histone modifications, and microRNA dysregulation modulate gene expression without altering the DNA sequence. Pro-oncogenic microRNAs are overexpressed, whereas those involved in maintaining glandular differentiation are reduced. These mechanisms promote stabilization of the malignant phenotype and clonal expansion.

The tumor microenvironment plays an active role in progression. The chronic inflammatory infiltrate, composed of lymphocytes, macrophages, activated fibroblasts, and myeloid cells, produces mediators such as IL-6, IL-8, TNF, and TGFβ, which promote proliferation, invasiveness, and local immunosuppression. Intratumoral hypoxia induces HIF-1α activation and stimulates VEGF-mediated angiogenesis, generating a disorganized vascular network that nevertheless supports neoplastic growth. At the same time, extracellular matrix remodeling facilitates cell migration.

At the immunological level, gastroesophageal junction tumors show a heterogeneous response. PD-L1 expression is variable and reflects immune-evasion mechanisms. Some subgroups, particularly those with high genomic instability, may display greater immunogenicity, whereas others are dominated by signs of T-cell exhaustion and accumulation of regulatory T cells and myeloid-derived suppressor cells.

Molecular analyses have proposed several major biological subtypes:

• chromosomally unstable subtype, with multiple amplifications and dominant proliferative signaling;
• inflammatory subtype, characterized by marked immune infiltration;
• metabolic subtype, with specific adaptations to hypoxia and nutrient stress.

From a histological perspective, most gastroesophageal junction tumors are adenocarcinomas with variable degrees of differentiation. Well-differentiated forms show relatively regular glands; moderately differentiated forms display greater architectural disorganization; poorly differentiated forms show solid or poorly cohesive patterns. Mucinous or signet-ring-cell variants may be present and are associated with more aggressive biological behavior.

Immunohistochemistry supports diagnostic and prognostic characterization: CK7, CK20, and CDX2 document glandular differentiation; HER2 may be overexpressed in a proportion of cases; Ki-67 provides information on the proliferative fraction. Lymphatic, vascular, and perineural invasion are morphological indicators of aggressiveness.

Experimental models, including patient-derived organoids and xenografts, have made it possible to reproduce clonal heterogeneity and investigate mechanisms of progression and resistance. Single-cell sequencing techniques are clarifying the organization of tumor and stromal populations and revealing distinct evolutionary trajectories. Overall, gastroesophageal junction tumors emerge as complex neoplasms resulting from the interaction of chronic inflammation, multiple molecular alterations, a permissive microenvironment, and metabolic adaptations.

The clinical manifestations of gastroesophageal junction tumors result from progressive impairment of food transit, infiltration of the wall, and the systemic effects of the disease. In the early stages, symptoms may be subtle or absent, particularly when the lesion is confined to the mucosa or submucosa. In such cases, the diagnosis may be made incidentally during endoscopic investigations performed for persistent reflux symptoms, iron-deficiency anemia, or follow-up of predisposing conditions.

The most common symptom is dysphagia, initially intermittent and predominantly affecting solid foods. Patients describe a sensation of the bolus slowing or stopping behind the sternum, often compensated for by drinking liquids. As the stenosis progresses, dysphagia becomes continuous and also involves semisolid foods and liquids. Odynophagia may occur, particularly in the presence of mucosal ulceration or nerve infiltration.

Reduced food intake and tumor-induced metabolic changes lead to progressive weight loss, often accompanied by fatigue and loss of muscle mass. Retrosternal or epigastric pain may be present and is sometimes mistaken for cardiac or dyspeptic symptoms. Regurgitation, sialorrhea, and a sensation of esophageal stasis may occur.

Clinical presentation varies according to the predominant location:

• gastroesophageal junction lesions: dysphagia associated with heartburn and regurgitation;
• lesions with gastric extension: epigastric pain, early satiety, and loss of appetite;
• lesions with esophageal extension: worsening dysphagia and retrosternal pain;
• at any site, progressive dysphagia and weight loss should prompt urgent evaluation.

Local progression may involve adjacent structures, causing persistent cough, dyspnea, and recurrent respiratory infections when the airways are affected. The formation of esophagotracheal fistulas is a serious complication, characterized by coughing during eating and frequent aspiration. Extension to the pleura, pericardium, or mediastinum may cause chest pain and serous effusions.

Chronic bleeding from the tumor surface may cause iron-deficiency anemia, whereas more substantial hemorrhage presents with hematemesis or melena. Advanced disease is often accompanied by cancer cachexia, with marked deterioration in general condition.

Regional lymphatic spread may present with supraclavicular or celiac lymphadenopathy. Distant metastases cause organ-specific symptoms, such as bone pain, dyspnea, or neurological signs. Physical examination commonly reveals signs of malnutrition, anemia, and reduced physical performance. The typical presentation is that of a middle-aged or older patient, often with a history of chronic reflux disease or gastric disease, reporting worsening dysphagia, weight loss, and fatigue.

The diagnostic workup for gastroesophageal junction tumors begins with a structured clinical suspicion and follows a sequence of investigations aimed at histologically confirming the neoplasm, establishing the correct etiological framework, and defining disease extent before formal staging. Clinical suspicion arises in the presence of progressive dysphagia, initially for solids and subsequently for liquids, involuntary weight loss, unexplained iron-deficiency anemia, persistent epigastric or retrosternal pain, refractory heartburn, acid regurgitation, or episodes of occult or overt gastrointestinal bleeding. These symptoms are particularly significant in individuals with chronic gastroesophageal reflux disease, Barrett esophagus, visceral obesity, male sex, older age, and a history of smoking. At this initial stage, the primary clinical objective is to recognize a suggestive presentation promptly and refer the patient for timely endoscopic assessment, avoiding low-yield preliminary investigations that may delay diagnosis.

The reference investigation for diagnosis is esophagogastroduodenoscopy, which is the first truly decisive specialist examination. International guidelines recommend EGD as the first-line test, without a routine need for contrast radiography except in selected circumstances, such as particularly tight stenoses or situations in which the safety of endoscopy is uncertain. The examination should be performed with high-definition equipment and accompanied by a detailed description of the lesion, including its location relative to the incisors, relationship to the Z-line, longitudinal extension above and below the junction, macroscopic appearance (exophytic, ulcerated, infiltrative, or stenosing), degree of luminal compromise, and ability to traverse the lesion with the endoscope. A complete assessment of the distal esophagus, junction, and proximal stomach is essential to identify the actual site of origin correctly.

In gastroesophageal junction tumors, advanced endoscopic imaging techniques play an important role, especially in early-stage disease and in cases arising in metaplastic mucosa. Techniques such as NBI, BLI, and FICE provide better characterization of the mucosal surface and vascular pattern, facilitating identification of early neoplastic areas and delineation of their margins. Optical magnification allows assessment of architectural and vascular irregularities that help distinguish dysplastic or neoplastic areas from inflamed or metaplastic mucosa, thereby contributing to more accurate lesion mapping.

During endoscopy, multiple biopsies are obtained and constitute the cornerstone of definitive diagnosis. Numerous representative samples should be taken from different areas of the lesion and its margins, including both the esophageal and gastric components, to reduce the risk of inconclusive findings due to histological heterogeneity or superficial necrosis. In the presence of a tight stenosis, small-caliber endoscopes may be used to reach the critical area and obtain adequate specimens. When repeated biopsies remain nondiagnostic despite a highly suspicious endoscopic appearance, macrobiopsies or diagnostic endoscopic procedures such as endoscopic mucosal resection or submucosal dissection may be considered, particularly for superficial tumors.

Histopathological analysis of the specimens provides the definitive diagnosis of a malignant gastroesophageal junction neoplasm, which in most cases is an adenocarcinoma. Hematoxylin and eosin staining shows atypical glandular structures, architectural disorganization, nuclear pleomorphism, and stromal infiltration. The pathologist establishes the degree of differentiation, assesses the presence of mucin, necrosis, vascular or perineural invasion, and uses immunohistochemistry in poorly differentiated or difficult-to-interpret cases to distinguish adenocarcinoma from squamous cell carcinoma, neuroendocrine neoplasms, or metastases from another primary site. Integration with the clinical context and predominant site of the lesion is essential for correct diagnostic attribution.

According to major international guidelines, a minimum set of clinical and pathological information must be available before a diagnosis of gastroesophageal junction tumor can be considered established and therapeutic decisions can be made; these elements are not formal diagnostic criteria, but constitute the essential requirements for a reliable diagnosis:

Elements required to establish a diagnosis of gastroesophageal junction tumor

• Endoscopic documentation of a suspicious lesion at the junction, with an accurate description of its anatomical relationships.
• Multiple representative biopsies of the lesion, repeated or supplemented by mucosal resection when findings are inconclusive.
• Histological demonstration of a malignant neoplasm, most commonly adenocarcinoma.
• Immunohistochemical support in poorly differentiated cases or when the differential diagnosis is complex.
• Clinical and instrumental assessment aimed at excluding a metastatic origin from another site.

Once histological confirmation has been obtained, the differential diagnosis must be addressed systematically. Gastroesophageal junction tumors must be distinguished from primary neoplasms of the distal esophagus and proximal stomach by integrating the site, longitudinal extension, and histological characteristics. Neuroendocrine neoplasms, gastrointestinal stromal tumors, lymphomas, and metastases must also be considered. Among non-neoplastic disorders, severe inflammatory lesions, complicated peptic ulcers, or cicatricial changes may mimic a tumor; in these cases, endoscopy with repeated biopsies and imaging allow the condition to be defined correctly.

After diagnosis has been confirmed, subsequent investigations focus on assessing disease extent. Endoscopic ultrasound allows detailed evaluation of the depth of wall infiltration and identification of suspicious regional lymph nodes. When lymph nodes have suggestive ultrasonographic features, endoscopic ultrasound-guided fine-needle aspiration provides cytological material that can confirm neoplastic involvement. Contrast-enhanced computed tomography of the chest and abdomen is essential for evaluating locoregional extension and distant metastases. 18F-FDG PET provides functional information useful for identifying metastatic sites not apparent on CT alone and for better characterizing suspicious lymph nodes.

In summary, the diagnostic assessment of gastroesophageal junction tumors follows a practical sequence: recognition of clinical suspicion; esophagogastroduodenoscopy with advanced imaging and multiple biopsies; histological confirmation with immunohistochemical support when needed; definition of the differential diagnosis; and then assessment of disease extent by endoscopic ultrasound, computed tomography, and PET.

The staging of gastroesophageal junction tumors integrates clinical, endoscopic, and radiological information and makes it possible to describe the anatomical extent of disease in a standardized manner, distinguish early from advanced forms, and provide prognostic guidance. The international reference is the eighth edition of the AJCC/UICC TNM system, which applies specific classification criteria to these neoplasms according to the predominant site of the lesion, distinguishing tumors staged according to the esophageal or gastric scheme.

Clinical staging is based on integrating endoscopic ultrasound findings, which are fundamental for assessing depth of infiltration and regional lymph-node status, with contrast-enhanced computed tomography of the chest and abdomen to evaluate locoregional extension and search for distant metastases. 18F-FDG PET contributes to the identification of metabolically active foci not apparent on CT alone and improves characterization of suspicious lymph nodes, allowing more accurate definition of the clinical stage.

The main prognostic determinants remain depth of mural infiltration, number of metastatic lymph nodes, and presence of distant metastases. The TNM system describes anatomical progression from superficial lesions confined to the mucosa to forms with systemic spread. Early tumors may have a favorable prognosis, whereas extensive lymph-node involvement and metastatic disease are associated with a substantial worsening of outcome.

Conceptually, the main stage groups of gastroesophageal junction tumors can be summarized as follows:

Main stage groups in gastroesophageal junction tumors (general concept, AJCC/UICC 8th edition)

• Stage 0: carcinoma in situ or intraepithelial neoplasia confined to the epithelium.
• Stage I: invasive tumor limited to superficial layers without lymph-node or distant metastases.
• Stage II: disease with deeper wall infiltration or limited lymph-node involvement.
• Stage III: locally advanced tumor with extensive lymph-node involvement but no distant metastases.
• Stage IV: presence of distant metastases, irrespective of T and N categories.

When a surgical specimen is available without preoperative treatment, pathological staging provides a more accurate prognostic assessment through direct analysis of depth of infiltration, number of lymph nodes examined and involved, resection-margin status, and presence of vascular or perineural invasion. In patients who have received preoperative treatment, ypTNM staging describes the extent of residual disease and distinguishes complete pathological responses from cases with substantial persistent tumor.

Survival curves show a clear correlation between stage and outcome. Cohorts treated with a multimodal approach show high survival rates in early disease and a progressive decline in advanced stages, with an unfavorable prognosis in metastatic disease. Achieving complete resection and making the diagnosis while disease is localized are the main factors associated with a favorable outcome.

In addition to anatomical stage, several additional prognostic factors influence the clinical course, including histological grade, lymph-node burden, vascular and perineural invasion, tumor volume, and the patient’s general condition. Performance status, nutritional status, and comorbidities significantly affect treatment tolerability and overall prognosis.

Overall, staging of gastroesophageal junction tumors is an integrated process combining anatomical extent, histological characteristics, and the patient’s condition. Early-stage disease may achieve meaningful long-term survival, whereas in advanced stages prognosis remains strongly influenced by lymph-node involvement and distant metastases, with clinical attention also directed toward symptom control and quality of life.

The treatment of gastroesophageal junction tumors requires a complex and strictly multimodal approach because these neoplasms arise in an anatomical and biological transition zone between the distal esophagus and proximal stomach. The therapeutic strategy integrates interventional endoscopy, surgery, chemotherapy, radiotherapy, and, in appropriate settings, immunotherapy, in a sequence determined by disease extent, anatomical classification, histological and molecular characteristics, general condition, and patient preferences. Management should take place within an experienced multidisciplinary team capable of balancing oncological objectives, surgical radicality, and preservation of function.

In very early forms confined to the mucosa (Tis or T1a) and lacking high-risk histological factors, endoscopic resection may be curative. Endoscopic mucosal resection is indicated for small, well-demarcated lesions, whereas endoscopic submucosal dissection (ESD) allows en bloc resection of larger lesions and accurate assessment of margins and depth of invasion. Patient selection requires extremely accurate staging to exclude lymph-node involvement. With negative margins and disease confined to the mucosa, resection may be considered definitive and followed by endoscopic surveillance. Documentation of submucosal invasion, positive or close margins, lymphovascular invasion, or perineural invasion instead requires additional treatment, generally surgery, or alternative strategies in patients who are not surgical candidates.

For locally advanced but potentially resectable disease, the standard approach in Western guidelines is neoadjuvant therapy followed by surgery. Both neoadjuvant chemoradiotherapy and perioperative chemotherapy are used for gastroesophageal junction tumors, with the choice guided by the exact site of the neoplasm, craniocaudal extent, histology, and institutional practice. Chemoradiotherapy combines platinum- and fluoropyrimidine-based regimens or carboplatin and paclitaxel with radiotherapy, generally at doses between 41.4 and 50.4 Gy, to reduce tumor volume and increase the likelihood of an R0 resection.

Perioperative chemotherapy is an established alternative, particularly for junctional tumors with greater gastric extension. Modern regimens combine a fluoropyrimidine, platinum compound, and taxane and are administered before and after surgery, providing early and prolonged systemic treatment. Reassessment after the preoperative phase by imaging and clinical evaluation is essential to confirm resectability and adapt the therapeutic strategy in the event of progression or clinically significant toxicity.

Surgery is a cornerstone of curative treatment. The aim is to achieve an R0 resection together with adequate lymphadenectomy. The choice of operation depends on the predominant tumor location and its extent. Options include distal esophagectomy with reconstruction, total gastrectomy, or combined esophagogastric procedures, with reconstruction using a gastric conduit or, when necessary, intestinal interposition. Surgical planning must balance oncological radicality against functional preservation.

The main technical variants include transthoracic and transhiatal approaches, with an intrathoracic or cervical anastomosis depending on the selected procedure. Minimally invasive and robotic approaches are increasingly used in high-volume centers, with potential advantages in reducing surgical trauma, respiratory complications, and recovery time. Determinants of outcome include resection-margin quality, adequacy of lymph-node dissection, perfusion of the reconstructive conduit, and anastomotic technique, balancing the risks of leakage and stenosis.

In patients with residual pathological disease after neoadjuvant therapy and surgery, adjuvant immunotherapy may be indicated. Clinical studies have shown that administration of a PD-1 inhibitor for a defined period after surgery improves recurrence-free survival compared with observation. Candidate selection is based on residual pathological stage, response to preoperative therapy, and individual risk profile, with careful consideration of comorbidities and potential immune-mediated toxicities.

For unresectable locally advanced tumors or patients who are not candidates for surgery, definitive chemoradiotherapy is a potentially curative option. Protocols combine cisplatin and a fluoropyrimidine or carboplatin and paclitaxel with radiotherapy, generally at total doses between 50 and 60 Gy, adapting volumes and fractionation to the site and proximity of critical organs. In cases of persistent or locally recurrent disease, salvage surgery may be considered in selected patients, whereas endoscopic or palliative local-control strategies are used in others.

In recurrent or metastatic disease, treatment is mainly palliative. First-line regimens include platinum and fluoropyrimidine combinations, often integrated with anti-PD-1 immunotherapy. Late-phase studies have demonstrated survival benefits from adding immunotherapy, with a greater effect in patients with higher PD-L1 expression. Taxanes, irinotecan, and other cytotoxic agents remain available in subsequent lines, with selection guided by previous response, tolerability, and clinical condition.

Management of mechanical complications, particularly dysphagia, is an integral part of treatment. Placement of self-expanding esophageal stents can rapidly improve food transit, either as a bridge to curative-intent treatments or for palliation. Palliative radiotherapy or endoluminal brachytherapy may be used to reduce obstruction and improve swallowing. Selected endoscopic procedures should be considered in light of prognosis, stenosis location, and expected duration of benefit.

Nutritional support and toxicity management are cross-cutting elements of the therapeutic pathway. Malnutrition and sarcopenia are common and adversely affect treatment tolerance and outcome. Early involvement of dietitians and dedicated teams allows individualized interventions including dietary adjustments, oral supplementation, and enteral or parenteral nutrition. Control of pain, dysphagia, and psychological burden requires an integrated approach, with early incorporation of palliative care for patients with complex symptoms or an unfavorable prognosis.

Follow-up and post-treatment surveillance of gastroesophageal junction tumors are structured components of care aimed at detecting local or distant recurrence early, monitoring late treatment complications, and ensuring adequate nutritional and functional support. The follow-up program is individualized according to initial stage, treatment received, and response achieved, within a dynamic multidisciplinary approach.

In patients treated with curative endoscopic resection for superficial disease, surveillance is predominantly endoscopic. Examinations aim to detect local recurrence and new dysplastic or neoplastic lesions arising in metaplastic or dysplastic mucosa. Endoscopies are performed more frequently during the first few years and may include advanced imaging techniques and targeted biopsies. In the absence of suspicious findings, intensive radiological follow-up is generally not indicated.

After curative-intent surgery, with or without neoadjuvant therapy, follow-up is multidimensional. During the first two or three years, when the risk of recurrence is greatest, clinical assessments are generally scheduled every 3–6 months and include symptom evaluation, physical examination, monitoring of nutritional status, and management of comorbidities. Contrast-enhanced CT of the chest and abdomen is used at regular intervals for oncological surveillance, whereas endoscopy is reserved for symptomatic patients or equivocal radiological findings.

In patients treated with definitive chemoradiotherapy, follow-up requires particular care because response assessment is complex. Initial evaluation is performed with CT and, in selected cases, 18F-FDG PET, while considering the risk of nonspecific post-treatment uptake. Endoscopy with targeted biopsies retains a central role in local assessment, particularly when persistent mucosal abnormalities or suggestive symptoms are present.

A cross-cutting element of follow-up is management of functional and nutritional sequelae. After esophagogastric surgery, dysphagia, bile reflux, dumping syndrome, early satiety, and chronic weight loss may occur. Nutritional and functional monitoring is essential to prevent malnutrition and sarcopenia. Patients who have received radiotherapy should also be monitored for late toxicities, including anastomotic stenosis, mediastinal fibrosis, radiation pneumonitis, and cardiac complications.

The overall duration of follow-up is generally at least five years, with greater intensity during the first two or three years and progressively longer intervals in disease-free patients. Thereafter, attention shifts toward management of long-term sequelae and comorbidities and prevention of additional clinically significant events. At every stage, follow-up should remain flexible and tailored to the individual patient, integrating oncological surveillance with quality-of-life assessment.

In summary, follow-up of gastroesophageal junction tumors requires a coordinated approach combining oncological monitoring, management of late complications, and nutritional and functional support, with the aim of preserving the best possible level of autonomy and quality of life over time.

Long-term quality-of-life considerations are central to the comprehensive management of patients with gastroesophageal junction tumors because of the anatomical complexity of the site and the substantial functional impact of treatment. As survival improves, the need to address chronic sequelae that may persist even in the absence of active disease becomes increasingly evident. Quality of life should therefore be assessed systematically and continuously during follow-up as an integral component of oncological care.

One of the main determinants is swallowing and digestive function. Surgical procedures involving the gastroesophageal junction, often with resection of the distal esophagus and proximal stomach, profoundly alter the physiology of food transit. Patients may experience residual dysphagia, early fullness, difficulty consuming large meals, and a lasting need to modify food consistency and meal frequency. In patients treated with chemoradiotherapy, fibrosis and cicatricial stenosis may contribute to persistent swallowing disorders. Periodic functional assessment and rehabilitation promote better long-term adaptation.

Gastroesophageal and bile reflux is a common problem, particularly after procedures that alter physiological antireflux mechanisms. Regurgitation, atypical heartburn, chronic cough, and sleep disturbances may persist and adversely affect daily well-being. Management is based mainly on dietary, postural, and behavioral measures requiring ongoing education and appropriate clinical monitoring.

Postprandial metabolic disturbances, including manifestations of early and late dumping syndrome, are important causes of functional and social limitation. Symptoms such as tachycardia, sweating, abdominal pain, diarrhea, or reactive hypoglycemia require lasting reorganization of eating habits, with small frequent meals and careful nutrient distribution. Long-term nutritional support is essential to foster autonomy and quality of life.

Nutrition and body composition directly influence long-term outcomes. Unintentional weight loss, loss of muscle mass, and malnutrition are common and are associated with greater frailty, reduced functional capacity, and poorer treatment tolerance. Longitudinal monitoring of weight, body composition, and nutritional intake, combined with individualized interventions, is essential to preserve overall well-being.

Treatment sequelae may also involve respiratory and vocal function. Chronic cough, reduced respiratory capacity, hoarseness, or vocal fatigue affect communication, working life, and social relationships. A multidisciplinary rehabilitation approach can reduce the impact of these disorders and promote functional recovery over time.

The psychological and psychosocial sphere plays a decisive role. The often complex and invasive treatment course for gastroesophageal junction tumors may leave persistent emotional consequences, including anxiety, depression, fear of recurrence, and altered body image. Dietary and functional limitations may reduce social participation and impair interpersonal relationships. Structured psychological support and ongoing communication with the care team promote better adaptation to long-term survivorship.

Overall, long-term quality of life depends on the healthcare system’s ability to provide integrated care that combines oncological surveillance with management of functional, nutritional, and psychological sequelae. In this context, quality of life is a priority clinical outcome and should be considered alongside traditional indicators when evaluating the overall success of treatment for gastroesophageal junction tumors.

Complications of gastroesophageal junction tumors arise from the interaction of disease progression, multimodal treatment strategies, and invasive procedures, creating a complex clinical picture that requires continuous surveillance and multidisciplinary management. From the early stages, obstruction of food transit may cause dysphagia, reduced caloric intake, and malnutrition, whereas the consequences of locoregional infiltration and systemic impairment predominate in advanced disease. Early assessment of nutritional and functional status is crucial because frailty and loss of lean mass increase the risk of infection and treatment-related toxicity.

Local progression causes increasingly severe dysphagia, potentially leading to complete inability to eat, with a higher risk of aspiration and aspiration pneumonia. Invasion of adjacent structures may cause persistent thoracoabdominal pain, chronic cough, dysphonia, and dyspnea. The formation of esophagorespiratory fistulas is one of the most serious complications and is associated with recurrent pulmonary infections and high mortality. In more advanced cases, erosion of major mediastinal or abdominal vessels may cause massive fatal hemorrhage, while cachexia, venous thromboembolism, and paraneoplastic syndromes contribute to overall clinical deterioration.

Gastroesophageal junction surgery carries a significant risk of complications. Respiratory complications, particularly pneumonia, are among the main causes of postoperative morbidity. Anastomotic leakage is a feared event and may result from perfusion problems or occur in association with local infection. Late anastomotic strictures may require repeated endoscopic dilations, with a cumulative risk of perforation. Chylothorax, due to thoracic duct injury during lymph-node dissection, causes substantial fluid and protein losses. Postoperative arrhythmias and recurrent laryngeal nerve injuries complete the spectrum of major surgical complications.

Chemoradiotherapy is associated with acute and late toxicities. Common manifestations include radiation esophagitis and gastritis, which cause pain, severe dysphagia, and worsening nutritional status. Cytopenias increase infectious and bleeding risks, whereas radiotherapy may cause radiation pneumonitis, mediastinal fibrosis, and pericarditis. Chronic esophagogastric stenosis may develop over time and, more rarely, esophagorespiratory or esophagoaortic fistulas, often with rapidly fatal progression.

Immunotherapy may induce immune-mediated adverse events affecting several organs. The most clinically significant complications include immune-mediated pneumonitis, colitis, hepatitis, thyroid and adrenal endocrinopathies, skin manifestations, and nephritis. Although rare, conditions such as immune-mediated myocarditis are associated with high mortality and require prompt recognition and treatment. Management of these toxicities requires close clinical and laboratory monitoring.

Endoscopic procedures used to treat dysphagia or superficial lesions carry specific risks. Self-expanding stents may cause pain, migration, ulceration, perforation, or fistulas, especially in fibrotic or previously irradiated tissues. Endoscopic dilation carries a risk of perforation that is greater in tight stenoses. Resection or ablation techniques may be complicated by bleeding, perforation, and late cicatricial stenosis.

Systemically, cancer cachexia, opportunistic infections, and thromboembolic events are major determinants of poor prognosis. Progressive functional decline requires a comprehensive approach that incorporates symptom control, nutritional support, and, when appropriate, palliative care at an early stage.

Effective management of complications is based on structured prevention, including early nutritional screening, optimization of respiratory function, pain control, physiotherapy, monitoring of comorbidities, and prompt recognition of signs of toxicity or infection. Multidisciplinary integration reduces the severity of adverse events, improves quality of life, and enables as many patients as possible to complete treatment pathways in the best possible clinical condition.